In this edition:
NEO: neoadjuvant olaparib in relapsed HGSOC
Cyclophosphamide + bevacizumab in recurrent ovarian cancer
BrUOG 354: nivolumab ± ipilimumab for (O)CCC
Atezolizumab vs. placebo + chemotherapy + bevacizumab in recurrent ovarian cancer
CARACO: RRPL in debulking surgery for advanced epithelial ovarian cancer
Menopausal hormone therapy & ovarian/endometrial cancers
SOC-1: Secondary cytoreduction in relapsed ovarian cancer
A cancer stem cell functional assay in recurrent platinum-resistant epithelial ovarian cancer
Please login below to download this issue (PDF)